Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

Completed · Phase 2 · Has a placebo group

Conditions studied: Cystic Fibrosis, Pancreatic Insufficiency

In brief

The purpose of this study is to determine the most effective dose of a new enzyme therapy on oral nutrient absorption in cystic fibrosis (CF) subjects with exocrine pancreatic insufficiency.

Key facts

Study ID
NCT00095732
Run by
Anthera Pharmaceuticals
People needed
129
Starts
2004-06-01
Expected to finish
2005-03-01
Last updated by the study team
2014-10-17

Who can join

Age: 7 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.